OS Therapies Incorporated OSTX

OS Therapies says WHO has approved the brand name Herlystic for OST-HER2 (daznelimgene lisbac), with the nonproprietary name already approved. The company says this enables early worldwide market access via regulatory submissions led by MHRA under Project Orbis, then the FDA, EMA and TGA. MHRA will coordinate submissions using non-concurrent historical controls from CPRD to support a CMAA in the U.K., while pursuing a U.S. BLA under Accelerated Approval based on surrogate endpoints and awaiting full 3-year OS data. OST-HER2 has FDA ODD, FTD and RPDD; EMA ODD/FTD/ATMP; and MHRA ODD/ATMP, with a recent $220 million PRV sale. Resubmission of RMAT and a pending CNPV letter are noted; the plan calls for CMAA in the U.K. in Q4 2026, followed by BLA in the U.S. and CMAAs in Europe and Australia. Strong regulatory progress and a clear path to accelerated, multi-jurisdictional market access for OST-HER2 could materially influence future approvals and value.

OS Therapies says MHRA SAM alignment enables a confirmatory Phase 3 for OST-HER2 in metastatic osteosarcoma in the U.K., using requalified Phase 2b material; CMAA submission expected in coming weeks and Phase 3 start in mid-2026. MHRA to lead global reviews under Project Orbis with FDA/EMA; access to the U.K. CPRD data will boost comparator quality during early market access. FDA aligned on the adaptive Phase 3 design; U.S. and Europe will allow Phase 3 to proceed with Phase 3-ready drug product, enabling 2027 expansion into the U.S. and Europe. OST-HER2 holds FDA ODD/FTD/RPDD and EMA ODD/FTD/ATMP; MHRA ODD/ATMP. A RMAT resubmission, CNPV intent accepted; a prior PRV sale occurred in Aug 2026 ($220M). CMAA in the U.K. and BLA under Accelerated Approval in the U.S. anticipated around 2026–27. Coordinated MHRA leadership and Project Orbis framework with pending BLA/CMAA approvals could materially accelerate OST-HER2's global market access and value.

OS Therapies achieves incremental alignment with FDA and accepts Project Orbis invitation from MHRA on OST-HER2 metastatic osteosarcoma program. FDA alignment and MHRA Project Orbis acceptance advance OST-HER2 towards approval and global markets.

OS Therapies has secured full alignment with UK MHRA and EU EMA for its Conditional Marketing Authorisation Application Filing. Regulatory alignment advances conditional marketing authorisation prospects in UK and EU markets.

OS Therapies achieves statistically significant overall survival benefit for OST-HER2-treated patients in interim 3-year analysis of phase 2b pulmonary metastatic osteosarcoma trial. Positive phase 2b survival data for lead candidate OST-HER2 signals major progress toward regulatory milestones and potential commercialization.

OS Therapies updates OST-HER2 metastatic osteosarcoma program and announces attendance at upcoming conferences. OST-HER2 program update signals advancement in primary therapeutic candidate.

OS Therapies Incorporated reported second quarter 2026 financial results and provided updates on business operations and regulatory matters. Quarterly financial reports combined with business and regulatory updates typically affect short-term valuation and investor sentiment without altering long-term trajectory.

OS Therapies (OSTX) secured U.S. FDA Type C Statistical Methods Meeting to review 2.5-year overall survival data for OST-HER2 in preventing or delaying recurrence of fully resected pulmonary metastatic osteosarcoma. FDA meeting advances regulatory review of OST-HER2 survival data for core osteosarcoma program.

OS Therapies accepts new FDA meeting request to review biomarker data as part of BEST Program. FDA biomarker review acceptance advances OS Therapies regulatory progress and potential approval path.

OS Therapies Incorporated released its third quarter 2026 corporate outlook detailing expected developments, strategies and performance guidance. Corporate outlook outlines forward plans that may moderately shape operations, financial results and investor views.

OS Therapies provided a U.S. regulatory update on its therapeutic programs, outlining agency feedback and next development steps. Regulatory clarity directly influences clinical timelines and financing prospects for OSTX.

OS Animal Health published peer-reviewed clinical trial data showing OST-HER2 plus palliative radiation as an effective frontline treatment in canine osteosarcoma. Positive peer-reviewed OST-HER2 data in dogs validates the core platform and may lift market sentiment toward OSTX human osteosarcoma programs.

OS Therapies secures global regulatory alignment on Phase 3 trial design for OST-HER2 in fully resected pulmonary metastatic osteosarcoma. Regulatory alignment advances OST-HER2 Phase 3 trial toward potential approval and revenue.

OS Therapies Incorporated (OSTX) will report significant survival benefit for OST-HER2 in osteosarcoma. Positive survival data for lead asset in osteosarcoma directly improves company trajectory and sentiment.

OS Therapies achieves statistically significant 2.5-year overall survival in Phase 2b trial of OST-HER2 in fully resected pulmonary metastatic osteosarcoma. Positive Phase 2b survival data for OST-HER2 marks a major clinical milestone likely to boost development prospects and investor sentiment for OSTX.

OS Therapies Incorporated (OSTX) appoints industry leader Dr. Craig Eagle as Chief Medical Advisor to guide clinical development and strategic initiatives. Appointing an experienced industry leader as Chief Medical Advisor enhances clinical expertise, credibility, and strategic positioning in drug development.

EMA initiates rolling review of OS Therapies' (OSTX) Conditional Marketing Authorization Application for OST-HER2 to prevent or delay recurrence in fully resected pulmonary metastatic osteosarcoma. EMA rolling review of OST-HER2 application marks significant regulatory milestone advancing OSTX's lead therapy toward potential conditional approval in orphan indication.

OS Therapies Incorporated (OSTX) schedules conference call on April 30, 2026 at 8:30am ET to discuss pharmacodynamic response biomarkers for OST-HER2. Scheduling a call on OST-HER2 pharmacodynamic biomarkers signals clinical development progress with moderate potential impact on investor sentiment and stock performance.

OS Therapies Incorporated (OSTX) filed a new patent application covering biomarkers of the immune response to Listeria monocytogenes. Patent filing on immune biomarkers enhances OSTX's IP protection for Listeria-based therapies, potentially aiding product innovation and competitive positioning.

OS Therapies Incorporated (OSTX) appoints biotech industry luminary Robert 'Bob' S. Langer, PhD, as Strategic Advisor. Appointing Robert Langer, a renowned biotech innovator, provides OSTX with elite strategic expertise to advance its oncology pipeline and boost market credibility.

OS Therapies Incorporated (OSTX) completed a $5.25 million registered direct offering, primarily with pre-existing high-net-worth investors. The $5.25M raise enhances OSTX's cash position to fund operations but represents moderate scale relative to biotech funding needs.

OS Therapies completed submission of biomarker and clinical data for U.S. FDA Pre-BLA meeting, reported full-year 2025 financial results, and provided business update. Pre-BLA submission advances key regulatory milestone toward potential drug approval, significantly impacting OSTX's trajectory and investor sentiment.

OS Therapies Incorporated (OSTX) granted meetings with U.S. FDA, U.K. MHRA, EMA, and Australian Therapeutic Goods Administration to review global confirmatory Phase 3 trial for OST-HER2 in metastatic osteosarcoma. Regulatory meetings for Phase 3 trial review with major global agencies signal major progress toward potential approvals, boosting OSTX's clinical and market trajectory.

OS Therapies Incorporated (OSTX) received the European Medicines Agency's (EMA) Advanced Therapy Medicinal Product (ATMP) designation for OST-HER2, targeting pulmonary recurrence in resected osteosarcoma. EMA's ATMP designation accelerates OST-HER2 development, provides regulatory benefits, and boosts OSTX's prospects in rare osteosarcoma treatment.

OS Therapies Incorporated (OSTX) announced the FDA elevated its OST-HER2 Type D meeting to a Type B Pre-BLA meeting, signaling advanced progress toward biologics license application submission. Elevating to Type B Pre-BLA meeting accelerates OST-HER2 regulatory pathway, significantly enhancing OSTX's development timeline and investor confidence.

OS Therapies Incorporated announced a global regulatory update for OST-HER2 targeting recurrent, fully resected pulmonary metastatic osteosarcoma. Global regulatory update on OST-HER2 advances OSTX's key pipeline asset in a rare cancer indication, potentially boosting investor sentiment and strategic positioning.

OS Therapies Incorporated (OSTX) has expressed strong support for the reauthorization of the Pediatric Priority Review Voucher Program, which aims to expedite the development of innovative treatments for pediatric diseases, including osteosarcoma. This program is expected to enhance the company's efforts in advancing breakthrough immunotherapies for osteosarcoma, potentially improving outcomes for affected children and facilitating faster access to critical therapies. The reauthorization of the Pediatric Priority Review Voucher Program is likely to significantly enhance OSTX's strategic positioning and market opportunities in developing osteosarcoma treatments.

OS Therapies Incorporated has initiated the filing of a Biologics License Application (BLA) with the US FDA for its product OST-HER2, aimed at preventing or delaying recurrent pulmonary metastatic osteosarcoma in patients who have undergone complete surgical resection. This step marks a significant advancement in the company's efforts to address this challenging cancer type. The BLA filing represents a major strategic move that could significantly impact the company's future performance and investor sentiment.

OS Therapies Incorporated announced positive biomarker data from its Phase 2b clinical trial of OST-HER2, aimed at preventing or delaying recurrent pulmonary metastatic osteosarcoma in patients with fully resected tumors. The trial results indicate promising efficacy, potentially enhancing treatment options for this challenging cancer type. Positive trial results could significantly impact the company's future performance and market positioning in oncology.

OS Therapies Incorporated has filed a Form S-1 for its OS Animal Health subsidiary, indicating plans for a potential public offering. This move aims to enhance the subsidiary's growth and development in the animal health sector, aligning with the company's strategic objectives. The filing of Form S-1 suggests a significant strategic move that could enhance the company's market position and investor sentiment.